Regenicin™ to Present at the Rodman & Renshaw Healthcare Conference

NEW YORK, Sept. 8 /PRNewswire/ -- Regenicin™ (OTC Bulletin Board: WDST), a clinical-stage company developing next-generation tissue-engineered skin substitutes to restore the qualities of healthy human skin, will present at the Rodman & Renshaw Healthcare Conference held at the New York Palace Hotel, New York City from September 12-15, 2010.

Regenicin™ President Joe Connell will speak on Wednesday, September 15th at 11:15 am EDT to provide a status update on the company's Pipeline lead candidate PermaDerm™ as well as a general overview of Regenicin™, which went public in August.

About the Rodman Healthcare Conference

The Rodman & Renshaw Annual Global Investment Conference will be held at the New York Palace Hotel September 12th-15th. Henry M. Paulson, Jr., 74th United States Secretary of the Treasury (2006-2009), will open the conference as the keynote speaker on Monday, September 13, 2010 in a moderated interview hosted by Lawrence Kudlow, renowned free market, supply-side economist and host of CNBC's The Kudlow Report. William Isaac, former Chairman of the Federal Deposit Insurance Corporation and author of the 2010 book Senseless Panic: How Washington Failed America, will also be a special guest speaker at the conference on Tuesday, September 14th, 2010 at 5:30 PM.

Following Mr. Paulson's opening program, more than 200 public and private companies from around the world are expected to present to an audience of over 3,500 attendees.

About Regenicin™

Regenicin™, Inc. is a clinical-stage company developing next generation tissue-engineered skin substitute to restore healthy human skin in severe burn victims. Through a strategic alliance with Lonza Group Ltd., the company has licensed breakthrough technology that utilizes a patient's own skin to generate living, tissue-engineered skin that has been used in clinical trials to treat burn victims.

With over 2,000 cases annually involving burns covering over 50% of a patient's body, according to the American Burn Association, the potential United States market size for Regenicin™'s product is in excess of $3 billion annually. The product could also be used for a wide variety of other applications, including the treatment of patients with chronic wounds or use in reconstructive plastic surgery.

As the key component to Regenicin™'s PermaDerm™ tissue-engineered skin, its biomedical polymer is an important commercial product that could be used for a variety of other applications separately, including as protection for organs and tendons, as a carrier for hormones or medicines, as a protective healing agent for wounds, or as a carrier for stem cells, making this company one worth watching for investors. (www.regenicin.com).

SOURCE Regenicin, Inc.